



156-158 Buckingham Palace Road, London, SW1W 9TR
Tel: +44 (0)20 7259 8482 – Fax: +44 (0)20 7259 8480

InterPharm Investments appoints Financial Advisor to Board of Directors

21st November 2011. InterPharm Investments Ltd., a ‘search and development’ company building a portfolio of patented medical foods, dietary supplements and medical devices, has appointed Rainer Lenz as a non-executive director. Rainer joins Mario Patrocollo and Elaine Evans on the Board of Directors.

Rainer Lenz is a Certified International Investment Analyst and Chartered Internal Auditor with extensive international experience, including over 10 years in the pharma industry. He has a proven track record in leading multi-national finance teams and developing businesses. He has worked on numerous M&A projects, from due diligence, equity valuation through to integration. Rainer is currently Vice President Internal Audit at Actavis, where he is responsible for carrying out the global internal audit program. Rainer has business and economics masters degrees from universities in the UK and France and from his native Germany.

Mario Patrocollo, InterPharm’s Chairman, said, “Having Rainer on the Board in these early stages of InterPharm’s growth is a great benefit as we progress with product development and in-licensing. Rainer’s input will be invaluable as InterPharm plans future fundraising activities.”

For further information, contact InterPharm’s CEO Elaine Evans at:
eevans@interpharminvestments.com

About InterPharm Investments Ltd www.interpharminvestments.com

InterPharm Investments Ltd develops patent-protected products which can be brought to market as medical foods, dietary supplements or medical devices and promoted for management of medical conditions. InterPharm identifies product opportunities from universities and spin-out companies and provides co-financing for product development in exchange for licensing rights. InterPharm has an affiliate company in Italy, InterAlia srl, which sells licensed-in oral care products to dentists and hygienists. InterAlia provides a first channel to market for new products from InterPharm’s pipeline.